Virilizing adrenal ganglioneuroma in a woman with subclinical Cushing syndrome

Endocrine Practice

Volumn 14, Issue 5, 2008, Pages 584-587

  Diab, Dima L ^a   Faiman, Charles ^a   Siperstein, Allan E ^a   Zhou, Ming ^a   Zimmerman, Robert S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CATECHOLAMINE; CORTICOTROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; INHIBIN; METADRENALIN; PRASTERONE SULFATE; PROTEIN S 100; TESTOSTERONE; TETRACOSACTIDE;

ADRENAL GLAND; ADRENALECTOMY; ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CASE REPORT; CATECHOLAMINE URINE LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GANGLIONEUROMA; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; OVARIECTOMY; POSTMENOPAUSE; POSTOPERATIVE COMPLICATION; PROVOCATION TEST; TESTOSTERONE BLOOD LEVEL; VIRILIZATION; ADRENAL TUMOR; BLOOD; DIFFERENTIAL DIAGNOSIS; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; LAPAROSCOPY; MIDDLE AGED;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; CUSHING SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; GANGLIONEUROMA; HUMANS; LAPAROSCOPY; MIDDLE AGED; POSTMENOPAUSE; TESTOSTERONE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 58149476681     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.5.584     Document Type: Article

References (25)

1. Geoerger B, Hero B, Harms D, Grebe J, Scheidhauer K, Berthold F. Metabolic activity and clinical features of primary ganglioneuromas. Cancer. 2001;91:1905-1913.
2. Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG, Lee JM. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics. 2003;23:29-43.
3. Lundy JB, Slane ML, Frizzi JD. Acute adrenal insufficiency after a single dose of etomidate. J Intensive Care Med. 2007;22:111-117.
4. Aguirre P, Scully RE. Testosterone-secreting adrenal ganglioneuroma containing Leydig cells. Am J Surg Pathol. 1983;7:699-705.
5. Godlewski G, Nguyen Trong AH, Tang J, Semler-Collery R, Joujoux JM, Gaujoux AF. Virilizing adrenal ganglioneuroma containing Leydig cells. Acta Chir Belg. 1993;93:181-184.
6. Takahashi H, Yoshizaki K, Kato H, et al. A gonadotrophin- responsive virilizing adrenal tumour identified as a mixed ganglioneuroma and adreno-cortical adenoma. Acta Endocrinol (Copenh). 1978;89:701-709.
7. Mack E, Sarto GE, Crummy AB, Carlson IH, Curet LB, Wu J. Virilizing adrenal ganglioneuroma. JAMA. 1978;239:2273-2274.
8. Parker LN, Odell WD. Evidence for existence of cortical androgen-stimulating hormone. Am J Physiol. 1979;236:E616-E620.
9. Novak DJ, Lauchlan SC, Mccawley JC, Faiman C. Virilization during pregnancy: case report and review of literature. Am J Med. 1970;49:281-290.
10. Ichikawa T, Ohtomo K, Araki T, et al. Ganglioneuroma: computed tomography and magnetic resonance features. Br J Radiol. 1996;69:114-121.
11. Radin R, David CL, Goldfarb H, Francis IR. Adrenal and extra-adrenal retroperitoneal ganglioneuroma: imaging findings in 13 adults. Radiology. 1997;202:703-707.
12. Linos DA, Stylopoulos N. How accurate is computed tomography in predicting the real size of adrenal tumors? A retrospective study. Arch Surg. 1997;132:740-743.
13. Lau H, Lo CY, Lam KY. Surgical implications of under-estimation of adrenal tumour size by computed tomography. Br J Surg. 1999;86:385-387.
14. Gopan T, Remer E, Hamrahian AH. Evaluating and managing adrenal incidentalomas. Cleve Clin J Med. 2006; 73:561-568.
15. Maser-Gluth C, Reincke M, Allolio B, Schulze E. Metabolism of glucocorticoids and mineralocorticoids in patients with adrenal incidentalomas. Eur J Clin Invest. 2000;30(suppl 3):83-86.
16. Petersenn S, Unger N, Walz MK, Mann K. Diagnostic value of biochemical parameters in the differential diagnosis of an adrenal mass. Ann N Y Acad Sci. 2006;1073:348-357.
17. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34:423-439, x.
18. Young WF Jr. Endocrine and biochemical evaluation of adrenal incidentaloma. In: Program and abstracts of the National Institutes of Health (NIH) State-of-the-Science Conference on Management of the Clinically Inapparent Adrenal Mass ("Incidentaloma") (pages 39-41); February 4-6, 2002; Bethesda, MD.
19. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab. 2001;86:5301-5306.
20. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878.
21. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85:1440-1448.
22. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87:998-1003.
23. Angeli A, Terzolo M. Adrenal incidentaloma - a modern disease with old complications. J Clin Endocrinol Metab. 2002;87:4869-4871.
24. Fernández-Real JM, Engel WR, Simó R, Salinas I, Webb SM (Study Group of Incidental Adrenal Adenoma). Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clin Endocrinol (Oxf). 1998;49:53-61.
25. Notelovitz M. Hot flashes and androgens: a biological rationale for clinical practice. Mayo Clin Proc. 2004;79(4 suppl):S8-S13.